LBA52 Tepotinib + Osimertinib for EGFRm NSCLC with MET Amplification (metamp) after Progression on First-Line (1L) Osimertinib: Initial Results from the INSIGHT 2 Study
ANNALS OF ONCOLOGY（2022）
Key words
Treatment Guidelines
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined